Last reviewed · How we verify
EC-MPS, Tacrolimus
EC-MPS, Tacrolimus is a Small molecule drug developed by Novartis Pharmaceuticals. It is currently FDA-approved.
At a glance
| Generic name | EC-MPS, Tacrolimus |
|---|---|
| Sponsor | Novartis Pharmaceuticals |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
- Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (PHASE3)
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients (PHASE4)
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (PHASE3)
- Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Kidney Transplant Recipients (PHASE4)
- Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate Sodium (PHASE3)
- A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EC-MPS, Tacrolimus CI brief — competitive landscape report
- EC-MPS, Tacrolimus updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI
Frequently asked questions about EC-MPS, Tacrolimus
What is EC-MPS, Tacrolimus?
EC-MPS, Tacrolimus is a Small molecule drug developed by Novartis Pharmaceuticals.
Who makes EC-MPS, Tacrolimus?
EC-MPS, Tacrolimus is developed and marketed by Novartis Pharmaceuticals (see full Novartis Pharmaceuticals pipeline at /company/novartis-pharmaceuticals).
What development phase is EC-MPS, Tacrolimus in?
EC-MPS, Tacrolimus is FDA-approved (marketed).
Related
- Manufacturer: Novartis Pharmaceuticals — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing